Form 4: Cytokinetics Director Harrington Receives Equity Grant

Director Robert Arthur Harrington acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Summary

• Director Robert Arthur Harrington was granted 2,851 shares of common stock at no cost.
• The director also received 4,301 non-qualified stock options with an exercise price of $77.15.
• The options vest starting June 27, 2026, and expire on May 26, 2036.
• Following these transactions, the director holds 21,781 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with shareholders through increased equity ownership.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term performance and align director interests with those of the shareholders.

Comparison to Industry Standards

• The grant of equity and options to directors is consistent with standard compensation packages for board members in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of stock options on June 27, 2026.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Equity Compensation, Director Compensation